Table 3.
Patient characteristics.
| All(n = 122) | Rivaroxaban (n = 49) | Apixaban(n = 50) | Dabigatran (n = 23) | |
|---|---|---|---|---|
| Mean age, years (range) | 83 (65–98) | 83 (66–98) | 84 (65–97) | 79 (67–91) |
| Women | 63 (52) | 26 (53) | 25 (50) | 12 (52) |
| Mean weight, kg (range) | 74 (40–165) | 70 (59–125) | 73 (40–165) | 82 (45–113) |
| Mean serum creatinine concentration, µmol/liter (range) | 88 (38–238) | 82 (38–125) | 92 (38–238) | 92 (51–160) |
| Mean creatinine clearance, ml/min (range) | 44 (19–91) | 45 (19–91) | 41 (19–88) | 50 (34–83) |
| Anticoagulation indication: | ||||
| AF | 101 (83%) | 33 (67%) | 47 (94%) | 21 (91%) |
| VTE treatment | 4 (3%) | 3 (6%) | 1 (2%) | 0 |
| VTE prophylaxis | 12 (10%) | 11 (22%) | 0 | 0 |
| AF and VTE treatment | 5 (4%) | 0 | 0 | 1 (4%) |
| CHADSVasc score (range) | 4.83 (2–8) | 4.43 (2–8) | 5.36 (2–8) | 4.57 (2–7) |
AF, atrial fibrillation; VTE, venous thromboembolism.